Advertisement

Disparities in Prostate Cancer

  • Otis W. Brawley
  • Sherrie Flynt Wallington
Chapter

Prostate cancer is the most commonly diagnosed non-skin cancer in the US and the second most common cause of cancer death among American men. In 2008 an estimated 186,320 men will be diagnosed with, and 28,660 will die of, prostate cancer in the US. Incidence rates increased dramatically in the 1990s attributable to prostate cancer screening but then declined after uncovering of prevalent cases. Mortality rates have trended downward in the past 15 years (Fig. 8.1).

Keywords

Prostate Cancer Radical Prostatectomy Prostate Cancer Risk Prostate Cancer Screening Sickle Cell Trait 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Akaza, H., Miyanaga, N., Takashima, N., Naito, S., Hirao, Y., Tsukamoto, T. et al. Comparisons of percent equal producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean, and American residents. Jap J Clin Oncol. 2004; 34(2):86–89.CrossRefGoogle Scholar
  2. Albano, J.D., Ward, E., Jemal, A., Anderson, R., Cokkinides, V.E, Murray, T. et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007; 99(18):1384–1394.PubMedCrossRefGoogle Scholar
  3. American Cancer Society (2009). Chief medical officer Otis W. Brawley responds to prostate cancer studies. American Cancer Society. Retrieved March 25, 2008, from http://www.cancer.org/docroot/MED/content/MED_2_1×_Chief_Medical_Officer_Otis_W_Brawley_Responds_to_Prostate_Studies.asp.
  4. Amling, C.L., Kane, C.J., Riffenburgh, R.H., Ward, J.F., Roberts, J.L., Lance, R.S. et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology. 2001; 58(5):723–728.PubMedCrossRefGoogle Scholar
  5. Amling, C.L., Riffenburg, R.H., Sun, L., Moul, J.W., Lance, R.S., Kusada, L. et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004; 22(3):439–445.PubMedCrossRefGoogle Scholar
  6. Andriole, G.L., Grubb, R.L., III, Buys, S.S., Chia, D., Church, T.R., Fouad, M.N., et al. Mortality results from a radomized prostate-cancer screening trial. New Engl J Med. 2009; 360(13). Retrieved March 26, 2009, from http://content.nejm.org/cgi/content/full/NEJMoa0810696.
  7. Austin, J.P., Convery, K. Age-race interaction in prostatic adenocarcinoma treated with external beam irradiation. Am J Clin Oncol. 1993; 16(2):140–145.PubMedCrossRefGoogle Scholar
  8. Austin, J.P., Aziz, H., Potters, L., Thelmo, W., Chen, P., Choi, K. et al. Diminished survival of young blacks with adenocarcinoma of the prostate. Am J Clin Oncol. 1990; 13(6):465–469.PubMedCrossRefGoogle Scholar
  9. Bangsi, D., Zhou, J., Sun, Y., Patel, N.P., Darga, L.L., Heilbrun, L.K. et al. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. Urol Oncol. 2006; 24(1):21–27.PubMedGoogle Scholar
  10. Bach, P.B., Schrag, D., Brawley, O.W., Galaznik, A., Yakren, S., Begg, C.B. Survival of black and whites after a cancer diagnosis. J Am Med Assoc. 2002; 287(16):2106–2113.CrossRefGoogle Scholar
  11. Barry, M.J. Screening for prostate cancer – The controversy that refuses to die. New Engl J Med. 2009; 360(13). Retrieved March 26, 2009, from http://content.nejm.org/cgi/content/full/NEJMe0901166.
  12. Bennett, C.L., Ferreira, M.R., Davis, T.C., Kaplan, J., Weinberger, M., Kuzel, T. et al. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol. 1998; 16(9):3101–3104.PubMedGoogle Scholar
  13. Bennett, C.L., Price, D.K., Kim, S., Liu, D., Jovanovic, B.D., Nathan, D. et al. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol. 2002; 20(17):3599–3604.PubMedCrossRefGoogle Scholar
  14. Ben-Shlomo, Y., Evans, S., Ibrahim, F., Patel, B., Anson, K., Chinegwundoh, F. et al. The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS cohort study. Eur Urology. 2008; 53(1):99–105.CrossRefGoogle Scholar
  15. Brawley, O.W. Some perspective on black-white cancer statistics. CA Cancer J Clin. 2002; 52(6):322–325.PubMedCrossRefGoogle Scholar
  16. Brawley, O.W. Population categorization and cancer statistics. Cancer Metastasis Rev. 2003; 22(1):11–19.PubMedCrossRefGoogle Scholar
  17. Brawley, O.W., Ford, L.G., Thompson, I., Perlman, J.A., Kramer, B.S. 5-Alpha reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev. 1994; 3(2):177–182.PubMedGoogle Scholar
  18. Brewster, D.H., Thomson, C.S., Hole, D.J., Black, R.J., Stroner, P.L., Gillis, C.R. Relation between socioeconomic status and tumor stage in patients with breast, colorectal, ovarian, and lung cancer: results from four national, population based studies. BMJ. 2001; 322(7290):830–831.PubMedCrossRefGoogle Scholar
  19. Boyle, P. Screening for prostate cancer: have you had your cholesterol measured? BJU Int. 2003; 92(3):191–199.PubMedCrossRefGoogle Scholar
  20. Brown, M.L., Potosky, A.L. The presidential effect: the public health response to media coverage about Ronald Reagan’s colon cancer episode. Pub Op Quarterly. 1990; 54(3):317–329.CrossRefGoogle Scholar
  21. Collin, S.M., Martin, R.M., Metcalfe, C., Gunnell, D., Albertsen, P.C., Neal, D. et al. Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study. Lancet Oncol. 2008; 9(5):445–452.PubMedCrossRefGoogle Scholar
  22. Connell, P.P., Ignacio, L., Haraf, D., Awan, A.M., Halpern, H., Abdalla, I. et al. Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience. J Clin Oncol. 2001; 19(1):54–61.PubMedGoogle Scholar
  23. Cooperberg, M.R., Lubeck, D.P., Meng, M.V., Mehta, S.S., Carroll, P.R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2006; 22(11):2141–2149.CrossRefGoogle Scholar
  24. de Koning, H.J., Auvinen, A., Berenguer-Sanchez, A., Calais da Silva, F, Ciatto, S., Denis, L. et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary Cancer trial. Int J Cancer. 2002; 97(2):237–244.PubMedCrossRefGoogle Scholar
  25. Du, X.L., Fang, S., Coker, A.L., Sanderson, M., Aragaki, C., Cormier, J.N. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer. 2006; 106(6):1276–1285.PubMedCrossRefGoogle Scholar
  26. Duffy, S.W., Nagtegaal, I.D., Wallis, M., Cafferty, F.H., Houssami, Warwick, J. et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epid. 2008; 168(1):98–104.CrossRefGoogle Scholar
  27. Edwards, B.K., Brown, M.L., Wingo, P.A., Howe, H.L., Ward, E., Ries, L.A. et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005; 97(19):1407–1427.PubMedCrossRefGoogle Scholar
  28. Etzioni, R., Penson, D.F., Legler, J.M., di Tommaso, D., Boer, R., Gann, P.H. et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002; 94(13):981–990.PubMedGoogle Scholar
  29. Fiscella, K., Williams, D.R. Health disparities based on socioeconomic inequities: implications for urban health care. Acad Med. 2004; 79(12):1139–1147.PubMedCrossRefGoogle Scholar
  30. Fowler, J.E., Bigler, S.A. Renfroe, D.L., Dabagia, M.D. Prostate specific antigen in black and white men after hormonal therapies for prostate cancer. J Urol. 1997; 158(1): 150–154.PubMedCrossRefGoogle Scholar
  31. Fowler, J.E., Jr., Terrell, F.L., Renfroe, D.L. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol. 1996; 156(5):1714–1718.PubMedCrossRefGoogle Scholar
  32. Freedland, S.J., Jalkut, M., Dorey, F., Sutter, M.E., Aronson, W.J. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology. 2000; 56(1):87–91.PubMedCrossRefGoogle Scholar
  33. Gilligan, T., Wang, P.S., Levin, R., Kantoff, P.W., Avorn, J. Racial differences in screening for prostate cancer in the elderly. Arch Int Med. 2004; 164:1858–1864.CrossRefGoogle Scholar
  34. Giovannucci, E. Vitamin D and cancer incidence in the Harvard cohorts. Ann Epid. 2009; 19(2):87–88.Google Scholar
  35. Giovannucci, E., Liu, Y., Platz, E.A., Stampfer, M.J., Willet, W.C. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007; 121(7):1571–1578.PubMedCrossRefGoogle Scholar
  36. Glover, F.E., Jr., Coffey, D.S., Douglas, L.L., Cadogan, M., Russell, H., Tulloch, T. et al. The epidemiology of prostate cancer in Jamaica. J Urol. 1998; 159(6):1984–1986.PubMedCrossRefGoogle Scholar
  37. Godley, P.A., Schenck, A.P., Amamoo, M.A., Schoenbach, V.J., Peacock, S., Manning, M. et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst. 2003; 95(22):1702–1710.Google Scholar
  38. Gordon, N.H. Association of education and income with estrogen receptor status in primary breast cancer. Am J Epid. 1995; 142(8):796–803.Google Scholar
  39. Greenlee, R.T., Murray, T., Bolden, S., Wing, P.A., Cancer Statistics, 50: 7–33, 2000.Google Scholar
  40. Gross, C.P., Smith, B.D., Wolf, E., Andersen, M. Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer. 2008; 112(4):900–908.PubMedCrossRefGoogle Scholar
  41. Haenszel, W. Studies of migrant populations. Am J Pub Health. 1985; 75(3):225–226.CrossRefGoogle Scholar
  42. Haenszel, W., Kurihara, M. Studies of Japanese migrants: mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst. 1968; 40(1):43–68.PubMedGoogle Scholar
  43. Halpern, M.T., Ward, E.M., Pavluck, A.L., Schrag, N.M., Bian, J., Chen, A.Y. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008; 9(3):222–231.PubMedCrossRefGoogle Scholar
  44. Harlan, L., Brawley, O., Pommerenke, F., Wali, P., Kramer, B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995; 13(1):93–100.PubMedGoogle Scholar
  45. Harlan, L.C., Coates, R.J., Block, G., Greenberg, R.S., Ershow, A., Forman, M. et al. Estrogen receptor status and dietary intakes in breast cancer patients. Epid. 1993; 4(1):25–31.CrossRefGoogle Scholar
  46. Harlan, L.C., Potosky, A., Gilliland, F.D., Hoffman, R., Albertsen, P.C., Hamilton, A.S. et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst. 2001; 93(24):1864–1871.PubMedCrossRefGoogle Scholar
  47. Hart, K.B., Wood, D.P., Jr., Tekyi-Mensah, S., Porter, A.T., Pontes, J.E., Forman, J.D. The impact of race on biochemical disease-free survival in early-stage prostate cancer patients treated with surgery or radiation therapy. Int J Rad Oncol Biol Phys. 1999; 45(5):1235–1238.CrossRefGoogle Scholar
  48. Hernandez, W., Grenade, C., Santos, E.R., Bonilla, C., Ahaghotu, C., Kittles, R.A. IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis. 2007; 28(10):2154–2159.PubMedCrossRefGoogle Scholar
  49. Ingles, S.A., Ross, R.K., Yu, M.C., Irvine, R.A., La, P.G., Haile, R.W. et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 1997; 89(2):166–170.PubMedCrossRefGoogle Scholar
  50. Irvine, R.A., Yu, M.C., Ross, R.K., Coetzee, G.A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 1995; 55(9):1937–1940.PubMedGoogle Scholar
  51. Iselin, C.E., Box, J.W., Vollmer, R.T., Layfield, L.J., Robertson, J.E., Paulson, D.F. Surgical control of clinically localized prostate carcinoma equivalent in African-American and white males. Cancer. 1998; 83(11):2353–2360.PubMedCrossRefGoogle Scholar
  52. Johnstone, P.A., Kane, C.J., Sun, L., Wu, H., Moul, J.W., McLeod, D.G. et al. Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. Radiology. 2002; 225(2):420–426.PubMedCrossRefGoogle Scholar
  53. Kane, C.J., Lubeck, D.P., Knight, S.J., Spitalny, M., Downs, T.M., Grossfeld, G.D. et al. Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE. Urology. 2003; 62(6):1035–1039.PubMedCrossRefGoogle Scholar
  54. Kidd, L.C., Paltoo, D.N., Wang, S., Chen, W., Akereyeni, F., Issacs, W. et al. Sequence variation within the 5’ regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk. Prostate. 2005;64(3):272–282.PubMedCrossRefGoogle Scholar
  55. Kim, J.A., Kuban, D.A, el-Mahdi, A.M., Schellhammer, P.F. Carcinoma of the prostate: race as a prognostic indicator in definitive radiation therapy. Radiology. 1995; 194(2):545–549.PubMedGoogle Scholar
  56. Kittles, R.A., Young, D., Weinrich, S., Hudson, J., Argyropoulos, G., Ukoli, F. et al. Extent of linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in human populations: implications for prostate cancer risk. Hum Genet. 2001; 109(3):253–261.PubMedCrossRefGoogle Scholar
  57. Klabunde, C.N., Potosky, A.L., Harlan, L.C., Kramer, B.S. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998; 36(9):1337–1348.PubMedCrossRefGoogle Scholar
  58. Klein, E.A. Selenium and vitamin E cancer prevention trial. Ann NY Acad Sci. 2004; 1031:234–241.PubMedCrossRefGoogle Scholar
  59. Klein, E.A., Silverman, R. Inflammation, infection, and prostate cancer. Curr Op Urol. 2008; 18(3):315–319.CrossRefGoogle Scholar
  60. Klein, E.A., Casey, G., Silverman, R. Genetic susceptibility and oxidative stress in prostate cancer: integrated model with implications for prevention. Urology 2006; 68(6):1145–1151.PubMedCrossRefGoogle Scholar
  61. Kramer, B.S., Brown, M.L., Prorok, P.C., Potosky, A.L., Gohagen, J.K. Prostate cancer screening: what we know and what we need to know. Ann Int Med. 1993; 119(9):914–923.PubMedGoogle Scholar
  62. Kripalani, S., Sharma, J., Justice, E., Justice, J., Spiker, C., Laufman, L.E. et al. Low-literacy interventions to promote discussion of prostate cancer: a randomized controlled trial. Am J Prev Med. 2007; 33(2):83–90.PubMedCrossRefGoogle Scholar
  63. Kumar, R.J., Baha Barqawi, A.B., Crawford, E.D. Epidemiology of prostate cancer. Business Briefing: US Oncology Review 2004: 42–45.Google Scholar
  64. Liu, L., Cozen, W., Bernstein, L., Ross, R.K., Deapen, D. Changing relationship between socioeconomic status and prostate cancer incidence. J Natl Cancer Inst. 2001; 93(9):705–709.PubMedCrossRefGoogle Scholar
  65. Litman, H.J., Bhasin, S., Link, C.L., Araujo, A.B., McKinlay, J.B. Serum androgen levels in black, Hispanic, and white men. J Clin Endocrin Metab. 2006; 91(11):4326–4334.CrossRefGoogle Scholar
  66. Lu-Yao, G., Albertsen, P.C., Stanford, J.L., Stukel, T.A., Walker-Corkery, E.S., Barry, M.J. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 2002; 325(7367):740.PubMedCrossRefGoogle Scholar
  67. Lu-Yao, G., Moore, D.F., Oleynick, J., DiPaola, R.S., Yao, S.L. Use of hormonal therapy in men with metastatic prostate cancer. J Urol. 2006; 176(2):526–531.PubMedCrossRefGoogle Scholar
  68. Mariotto, A.B., Etzioni, R., Krapcho, M., Feuer, E.J. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer. 2007; 109(9):1877–1886.PubMedCrossRefGoogle Scholar
  69. McLeod, D.G., Schellhammer, P.F., Vogelzang, N.J., Soloway, M.S., Sharifi, R., Black, N.L. et al. Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. Prostate. 1999; 40(4):218–224.PubMedCrossRefGoogle Scholar
  70. Miller, D.C., Gruber, S.B., Hollenbeck, B.K., Montie, J.E., Wei, J.T. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006; 98(16):1134–1141.PubMedCrossRefGoogle Scholar
  71. Morris, C.R., Snipes, K.P., Schlag, R., Wright, W.E. Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States). Cancer Causes Control. 1999; 10(6):503–511.PubMedCrossRefGoogle Scholar
  72. Moul, J., Douglas, T., McCarthy, W., McLeod, D. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol. 1996; 155(5):1667–1672.PubMedCrossRefGoogle Scholar
  73. Nielsen, M.E., Han, M., Mangold, L., Humphreys, E., Walsh, P.C., Partin, A.W. et al. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urol. 2006; 176(2): 515–519.PubMedCrossRefGoogle Scholar
  74. Oakley-Girvan, I., Kolonel, L.N., Gallagher, R.P., Wu, A.H., Felberg, A., Whittemore, A.S. Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients. Am J Pub Health. 2003; 93(10):1753–1759.CrossRefGoogle Scholar
  75. Odedina, F.T., Ogunbiyi, J.O., Ukoli, F.A. Roots of prostate cancer in African-American men. J Natl Med Assn. 2006; 98(4):539–543.Google Scholar
  76. Pan, C.C., Lee, J.S., Chan, J.L., Sandler, H.M., Underwood, W., McLaughlin, P.W. The association between presentation PSA and race in two sequential time periods in prostate cancer patients seen at a university hospital and its community affiliates. Int J Rad Oncology, Biology, Physics. 2003; 57(5):1292–1296.CrossRefGoogle Scholar
  77. Panz, V.R., Joffe, B.I., Spitz, I., Lindenberg, T., Farkas, A., Haffejee, M. Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white men. Endocrine. 2001; 15(2):213–216.PubMedCrossRefGoogle Scholar
  78. Park, J., Chen, L., Ratnashinge, L., Sellers, T.A., Tanner, J.P., Lee, J.H. et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer, Epidemiology, Biomarkers, and Prevention. 2006; 15(8):1473–1478.CrossRefGoogle Scholar
  79. Parkin, D.M., Whelan, S.L., Ferlay, J., Raymond, L., Young, J., eds. Cancer Incidence in Five Continents, Vol 7. Lyon (France), IARC Scientific Publication No. 143, IARC Press; 1997.Google Scholar
  80. Peters, N., Armstrong, K. Racial differences in prostate cancer treatment outcomes. Cancer Nurs. 2005; 28(2):108–116.PubMedCrossRefGoogle Scholar
  81. Phillips, A.A., Jacobson, J.S., Magai, C., Consedine, N., Horowicz-Mehler, N.C., Neugut, A.I. Cancer incidence and mortality in the Caribbean. Cancer Invest. 2007; 25(6):476–483.PubMedCrossRefGoogle Scholar
  82. Platz, E.A., Rimm, E.B., Willett, W.C., Kantoff, P.W., Giovannucci, E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst. 2000; 92(24):2009–2017.PubMedCrossRefGoogle Scholar
  83. Polednak, A.P. Stage at diagnosis of prostate cancer in Connecticut by poverty and race. Ethnicity and Disease. 1997; 7(3):215–220.PubMedGoogle Scholar
  84. Potosky, A.L., Feuer, E.J., Levin, D.L. Impact of screening on incidence and mortality in the United States. Epidem Rev. 2001; 23(1):181–186.Google Scholar
  85. Powell, I.J., Dey, J., Dudley, A., Pontes, J.E., Cher, M.L., Sakr, W. et al. Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. Urol. 2002; 59: 907–912.PubMedCrossRefGoogle Scholar
  86. Powell, I.J., Land, S.J., Dey, J., Heilbrun, L.K., Hughes, M.R., Sakr, W. et al. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer. 2005; 103(3):528–537.PubMedCrossRefGoogle Scholar
  87. Reed, A., Ankerst, D.P., Pollack, B.H., Thompson, I.M., Parekh, D.J. Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer. J Urol. 2007; 178(5):1929–1932.PubMedCrossRefGoogle Scholar
  88. Ries L.A.G., Melbert, D., Krapcho, M., Stinchcomb, D.G., Howlader, N., Horner, M.J., Mariotto, A., Miller, B.A., Feuer, E.J., Altekruse, S.F., Lewis, D.R., Clegg, L., Eisner, M.P., Reichman, M., Edwards, B.K., (Eds). SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
  89. Ries, L.A.G., Harkins, D., Krapcho, M., Mariotto, A., Miller, B.A., Feuer, E.J. et al. SEER cancer statistic review, 1975–2003. Bethesda: National Cancer Institute, 2006 http://www.seercancer.gov/csr/1975–2002. Accessed August 4, 2008.
  90. Roach, M., III. Krall, J., Keller, J.W., Perez, C.A., Sause, W.T., Doggett, R.L. et al. The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group protocols (1976–1985). Int J Rad Oncol Biol Phys. 1992; 24(3):441–449.CrossRefGoogle Scholar
  91. Robbins, A.S., Whittemore, A.S., Thom, D.H. Differences in socioeconomic status and survival among white and black men with prostate cancer. Am J Epidem. 2000; 151(4):409–416.Google Scholar
  92. Robbins, A.S., Yin, D., Parikh-Patel, A. Differences in prognostic factors and survival among white men and black men with prostate cancer, California, 1995–2004. Am J Epidem. 2007; 166(1):71–78.CrossRefGoogle Scholar
  93. Rodriguez, C., McCullough, M.L., Mondul, A.M., Jacobs, E.J., Chao, A., Patel, A.V. et al. Meat consumption among blacks and white men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidem Biomarkers Prev. 2006; 15(2):211–216.CrossRefGoogle Scholar
  94. Roetzheim, R.G., Pal, N., Tennant, C., Voti, L., Ayanian, J.Z., Schwabe, A. et al. Effects of health insurance and race on early detection of cancer. J Natl Cancer Inst. 1999; 91(16):1409–1415.PubMedCrossRefGoogle Scholar
  95. Rohrmann, S., Nelson, W.G., Rifai, N., Brown, T.R., Dobs, A., Kanarek, N. et al. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endo Met. 2007; 92(7):2519–2525.CrossRefGoogle Scholar
  96. Ross, R.K. The role of molecular genetics in chemoprevention studies of prostate cancer. IARC Scientific Publications. 2001; 154:207–213.PubMedGoogle Scholar
  97. Ross, L.E., Berkowitz, Z., Ekwueme, D.U. Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey. Cancer, Epidemiology, Biomarkers, and Prevention. 2008; 17(3):636–644.CrossRefGoogle Scholar
  98. Ross, R.K., Pike, M.C., Coetzee, G.A., Reichardt, J.K., Yu, M.C., Feigelson, H. et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 1998; 58(20):4497–4504.PubMedGoogle Scholar
  99. Sakr, W.A., Billis, A., Ekman, P., Wilt, T., Bostwick, D.G. Epidemiology of high-grade prostatic intraepithelial neoplasia. Scand J Urol Nephr. Supp, 2000; 205:11–18.CrossRefGoogle Scholar
  100. Sakr, W.A., Grignon, D.J., Crissman, J.D., Heilbrun, L.K., Cassin, B.J., Pontes, J.J. et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. In Vivo. 1994; 8(3):439–443.PubMedGoogle Scholar
  101. Salam, M.T., Ursin, G., Skinner, E.C., Dessissa, T., Reichardt, J.K. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol. 2005; 23(4):246–253.PubMedGoogle Scholar
  102. Sanchez-Chapado, M., Olmedilla, G., Cabeza, M., Donat, E., Ruiz, A. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate. 2003; 54(3):238–247.PubMedCrossRefGoogle Scholar
  103. Sarter, O., Zheng, Q., Eastham, J.A. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urol. 1999; 53(2):378–380.CrossRefGoogle Scholar
  104. Satia-Abouta, J., Patterson, R.E., Schiller, R.N., Kristal, A.R. Energy from fat is associated with obesity in U.S. men: results from the Prostate Cancer Prevention Trial. Prev Med. 2002; 34(5):493–501.PubMedCrossRefGoogle Scholar
  105. Schro¨der, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Ciatto, S., Nelen, V., et al. Screening and prostate-cancer mortality in a randomized European study. New Engl J Med. 2009; 360(13). Retrieved March 26, 2009, from http://content.nejm.org/cgi/content/full/NEJMoa0810084.
  106. Schumacher, F.R., Feigelson, H.S., Cox, D.G., Haiman, C.A., Albanes, D., Buring, J. et al. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res. 2007; 67(7):2951–2956.PubMedCrossRefGoogle Scholar
  107. Schwartz, K.L., Crossley-May, H., Vigneau, F.D., Brown, K., Banerjee, M. Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control. 2003; 14(8):761–766.PubMedCrossRefGoogle Scholar
  108. Shavers, V.L., Brown, M.L. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 94(5):334–357.Google Scholar
  109. Shavers, V.L., Brown, M.L., Potosky, A.L., Klabunde, C.N., Davis, W.W., Moul, J.W. et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J General Int Med. 2004; 19(2): 146–155.CrossRefGoogle Scholar
  110. Shekarriz, B., Tiguert, R., Upadhyay, J., Gheiler, E., Powell, I.J., Pontes, J.E. et al. Impact of location and multifocality of positive surgical margins on disease-free survival following radical prostatectomy: a comparison between African-American and white men. Urol. 2000; 55(6):899–903.PubMedCrossRefGoogle Scholar
  111. Shibata, A., Ma, J., Whittemore, A.S. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst. 1998; 90(16):1230–1231.PubMedCrossRefGoogle Scholar
  112. Shibata, A., Whittemore, A.S. Re: Prostate cancer incidence and mortality in the United States and the United Kingdom. (Letter). J Natl Cancer Inst. 2001; 93(14):1109–1110.PubMedCrossRefGoogle Scholar
  113. Soos, G., Tsakiris, I., Szanto, J., Turzo, C., Haas, P.G., Dezso, B. The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. Eur Urol. 2005; 48(5):739–744.PubMedCrossRefGoogle Scholar
  114. Spangler, E., Zeigler-Johnson, C.M., Coomes, M., Malkowicz, S.B., Wein, A., Rebbeck, T.R. Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men. J Urol. 2007; 178(5):1939–1944.PubMedCrossRefGoogle Scholar
  115. Stangelberger, A., Waldert, M., Djavan, B. Prostate cancer in elderly men. Rev Urol. 2008; 10(2):111–119.PubMedGoogle Scholar
  116. Steenland, K., Rodriguez, C., Mondul, A., Calle, E.E., Thun, M. Prostate cancer incidence and survival in relation to education (United States). Cancer Causes Control. 2004; 15(9):939–945.PubMedCrossRefGoogle Scholar
  117. Tannock, I.F., de Wit, R., Horti, J., Pluzanska, A., Chi, K.N. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, NEJM. 2004; 351(15):1502–1512.PubMedCrossRefGoogle Scholar
  118. Tarman, G.J., Kane, C.J., Moul, J.W., Thrasher, J.B., Foley, J.P., Wilhite, D. et al. Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urol. 2000; 56(6):1016–1020.PubMedCrossRefGoogle Scholar
  119. Taylor, K.L., Davis, J.L., III., Turner, R.O., Johnson, L., Schwartz, M.D., Kerner, J.F. et al. Educating African American men about the prostate cancer screening dilemma: A randomized intervention. Cancer Epidem Biomarkers Prev. 2006; 15:2179–2188.CrossRefGoogle Scholar
  120. Telesca, D., Etzioni, R., Gulati, R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics. 2007; 64(1):10–19.PubMedCrossRefGoogle Scholar
  121. Thompson, I.M., Ankerst, D.P., Chi, C., Goodman, P.J., Tangen, C.M., Lucia, M.S. et al. Assessing prostate cancer risk: results form the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006; 98(8):529–534.PubMedCrossRefGoogle Scholar
  122. Thompson, I.M., Basler, J.A., Leach, R., Troyer, D., Klein, E., Brawley, O. Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer. Urol Oncol. 2003; 21(1):73–78.PubMedGoogle Scholar
  123. Thompson, I.M., Goodman, P.J., Tangen, C.M., Lucia, M.S., Miller, G.J., Ford, L.G. et al. The influence of finasteride on the development of prostate cancer, NEJM. 2003; 349(3):215–224.PubMedCrossRefGoogle Scholar
  124. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Task Force Recommendation Statement. Ann Int Med. 2008; 149 (3):185–191.Google Scholar
  125. Vogt, T.M., Ziegler, R.G., Patterson, B.H., Graubard, B.I. Racial differences in serum selenium concentration: analysis of US population data from the Third National Health and Nutrition Examination Survey. Am J Epidem. 2007; 166(3):280–288.CrossRefGoogle Scholar
  126. Williams, D.R. Race, health, and health care. St. Louis Univ Law J. 2003; 48(1):13–35.PubMedGoogle Scholar
  127. Williams, D.R. The health of men: Structured inequalities and opportunities. Am J Pub Health. 2003; 93(5):724–731.CrossRefGoogle Scholar
  128. Williams, D.R. The health of U.S. racial and ethnic populations. Journal of Gerontology. Series B. Psych Sci Soc Scie. 2005; 60(2):53–62.Google Scholar
  129. Williams, D.R., Collins, C. U.S. socioeconomic and racial differences in health. Annual Review of Sociology. 1995; 21:349–386.CrossRefGoogle Scholar
  130. Williams, D.R., Jackson, P.B. Social sources of racial disparities in health. Health Affairs (Millwood). 2005; 24(2):325–334.CrossRefGoogle Scholar
  131. Wolf, M.S., Knight, S.J., Lyons, E.A., Durazo-Arvizu, R., Pickard, S.A., Arseven, A. et al. Literacy, race, and PSA level among low-income men newly diagnosed with prostate cancer. Urol. 2006; 68(1):89–93.PubMedCrossRefGoogle Scholar
  132. Wood, H.M., Reuther, A.M., Gilligan, T.D., Kupelian, P.A., Modlin, C.S., Jr., Klein, E.A. Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migration. Journal of Urology. 2007; 178(4 Pt 1):1271–1276.PubMedCrossRefGoogle Scholar
  133. Yao, S.L., Lu-Yao, G. Understanding and appreciating overdiagnosis in the PSA era. J Nat Cancer Inst. 2002; 94(13):958–960.PubMedGoogle Scholar
  134. Young, C.D., Lewis, P., Weinberg, V., Lee, T.T., Coleman, C.W., Roach, M, III. The impact of race on freedom from prostate-specific antigen failure in prostate cancer patients treated with definite radiation therapy. Semin Urol Oncol. 2000; 18(2):121–126.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Chief Medical Officer, American Cancer Society, Professor of Hematology, Oncology, Medicine and EpidemiologyEmory UniversityAtlantaUSA
  2. 2.Postdoctoral Fellow, Harvard School of Public HealthBostonUSA

Personalised recommendations